The Federal Trade Commission (FTC) has released its second interim staff report highlighting the significant price markups imposed by major pharmacy benefit managers (PBMs), including CVS, Cigna, and UnitedHealth. The report alleges that these companies collectively netted approximately $7.3 billion from inflating the prices of specialty drugs, which has a detrimental impact on consumers and the U.S. healthcare system. Lawmakers, including Senator Elizabeth Warren, are pressing the FTC to take further action against these PBMs, emphasizing the need for greater transparency and accountability in the healthcare pricing mechanism.